GENBGenerate Biomedicines, Inc.
Is it safe?
Nothing alarming, nothing pristine: insiders quiet and big price swings.
Insiders were net sellers (-$16K, 90 days to Oct 8, 2026), selling is often routine.
Large price swings, high volatility. Worst drawdown -34% · now 30% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can GENB take a bad year?
The deepest fall in GENB's price history on file is −34%; it is 30% below its high today.
Worst drawdown on file · −30% today
- Annualised volatility
- 89%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $457M
- Annualised volatilitytwo years of daily moves
- 89%
- Worst drawdown on file
- −34%
- Below its 52-week high
- 30%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry